Boiron (FRA:BON) Gross-Profit-to-Asset % : 54.56% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Boiron's annualized Gross Profit for the quarter that ended in Dec. 2023 was €366.3 Mil. Boiron's average Total Assets over the quarter that ended in Dec. 2023 was €671.5 Mil. Therefore, Boiron's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 54.56%.

Boiron Gross-Profit-to-Asset % Historical Data

The historical data trend for Boiron's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Gross-Profit-to-Asset % Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

56.15

51.06

42.21

48.68

51.91

Boiron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															51.39	44.74	53.16	45.37	54.56

Competitive Comparison of Boiron's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Boiron's Gross-Profit-to-Asset % falls into.

Boiron Gross-Profit-to-Asset % Calculation

Boiron's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	358.083	/	( (789.493	+	590.201)	/ 2 )
	=	358.083	/	689.847
	=	51.91 %

Boiron's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	366.332	/	( (752.779	+	590.201)	/ 2 )
	=	366.332	/	671.49
	=	54.56 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Boiron Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Boiron's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.